The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Based on the following “ We also know that they were screening for cohort 4 so presumably must have received approval from the Safety Review Board to increase the dose.”. I assume that SC git the green light to progress.
If indeed the prime purpose is to stand by their poster, then any discussion we be centred around published data. Unpublished data will require RNS. Really puzzling what could be the motives of LD is not taking the podium.
Vulpes have taken a different approach: This is what Scancell would be worth IF SUCCESSFUL.
To come up with this approach is imho an indication that they have a good degree of confidence (>50%) of the outcome…speculative..maybe but has to be a very good reason behind the publication of their note.
…let’s sort out the production capabilities and then figure out what to produce…great plan for the Israeli government to produce quickly another virus vaccine and not necessary cancer treatment. Well every dev is a good one and let’s hope SC can take to market something before putin increases the sea level.
A cancer vaccine factory: Biotech's plan in Jerusalem
In the first phase, the plant will produce the company's vaccines against cancer, which have not yet been commercially approved, and will employ about 200-300 workers
We can expect second payment this month? If so and if im not mistaken it should be third of the first payment ?
No explicit info regarding the split cohorts.
It would be a fair assumption to conclude that RNS relates to cohort-1. Hence, the following is still outstanding:
Cohort -2 increase dose
Cohort -3 > cohort -1 dose + CPI
Cohort -4 > cohort -2 + increased CPI
AIMHO good luck
Fellas, this is AIM, for the love of G-d, stop wining, if there is no sense cut you losses and move on. Regardless of RNS content MM will act on market pressure. Someone decide to call it a day and close 3M position or trim down we have to take it on the chin. The share is oversold and pricy will slowly rectify the true value.
From pure investment perspective it is to do with ETA and commercialisation , agreement collaboration etc, with moderns they have a track record of on flow of cash , we are still waiting for this to happen , 12 years another year or two would not make much of a difference, that is why sclp is AIM with market value of £180m. When breakthrough will be announced , science , Merck takeover or others then will SP will reflect that. In the meantime we wish sincere good luck to every patient in their cohorts and we wait patiently for a better future. If you want to trade, be my guest buy low sell high…when I try that I realise I do the reverse.
Was golden nuggets phrase used in a manner which was not aligned with the scale of the breakthrough that was described in details in her mail ti the chairman?
If that is the case then as someone mentioned on the thread , we will be lucky to come out showing ROI. I would like to think that golden nuggets are exactly what to indent to highlight.